Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nektar Therapeutics (NASDAQ:NKTR)

24.10
BATS BZX Real-Time Price
As of 9:46am ET
 +0.17 / +0.71%
Today’s Change
11.41
Today|||52-Week Range
24.25
+96.41%
Year-to-Date
AstraZeneca Stock Rising in '17: What's Working in its Favor?
Mar 23 / Zacks.com - Paid Partner Content
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
Mar 21 / Zacks.com - Paid Partner Content
4 Biotech Stocks to Watch
Mar 22 / GuruFocus News - Paid Partner Content
New painkiller aims to avoid buzz that feeds addiction
Mar 20 / FT.com - Paid Partner Content
Biotech Stock Roundup: Amgen Down on Repatha Data, Nektar Surges on Pain Results
Mar 22 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close23.93
Today’s open23.93
Day’s range23.93 - 24.25
Volume1,775
Average volume (3 months)1,605,553
Market cap$3.7B
Dividend yield--
Data as of 9:46am ET, 03/29/2017

Growth & Valuation

Earnings growth (last year)-80.33%
Earnings growth (this year)-14.94%
Earnings growth (next 5 years)-7.38%
Revenue growth (last year)-28.32%
P/E ratioNM
Price/Sales10.35
Price/Book41.60

Competitors

 Today’s
change
Today’s
% change
BLUEbluebird bio Inc+0.77+0.84%
TECHBio-Techne Corp-0.12-0.12%
NBIXNeurocrine Bioscienc...+0.06+0.15%
KITEKite Pharma Inc-0.57-0.73%
Data as of 9:45am ET, 03/29/2017

Financials

Next reporting dateMay 3, 2017
EPS forecast (this quarter)-$0.39
Annual revenue (last year)$165.4M
Annual profit (last year)-$153.5M
Net profit margin-92.80%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Howard W. Robin
Chief Operating Officer &
Senior Vice President
John Nicholson
Corporate headquarters
San Francisco, California

Forecasts


Search for Jobs